sponsored
PatientsVille.com Logo

PatientsVille

Zoloft Medical Research Studies

Up-to-date List of Zoloft Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Zoloft Medical Research Studies

Rank Status Study
1 Recruiting Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline
Condition: Anxiety Disorder of Adolescence
Interventions: Drug: Sertraline;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Clinical Global Impression Severity & Improvement Scales;   Multidimensional Anxiety Scale for Children
2 Recruiting Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline
Condition: Posttraumatic Stress Disorder
Interventions: Behavioral: Prolonged exposure (PE);   Other: PE plus Sertraline
Outcome Measures: Posttraumatic stress disorder (PTSD) Symptoms;   Depression symptoms
3 Recruiting PROlonGed ExpoSure Sertraline
Condition: Posttraumatic Stress Disorder
Interventions: Drug: Sertraline;   Behavioral: Prolonged Exposure Therapy
Outcome Measures: Posttraumatic stress disorder (PTSD) symptoms as measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS);   Posttraumatic stress disorder (PTSD) related psychopathology, including depression, alcohol and substance abuse, and general anxiety
4 Recruiting Chronic Kidney Disease Antidepressant Sertraline Trial
Conditions: Chronic Kidney Disease;   Depression
Interventions: Drug: Sertraline;   Drug: placebo
Outcome Measures: Improvement in depression symptom severity as measured by the QIDS-C-16 score.;   Response to treatment defined as a decline of 50% in the baseline QIDS-C-16 score and remission of depression defined as a QIDS-C-16 score of 5;   Improvement in overall function as assessed by the Work and Social Adjustment Scale;   Improvement in quality of life;   Serious adverse events;   Reduction in platelet aggregation and activation in sertraline vs. placebo group, and whether this reduction correlates with higher plasma sertraline levels.;   Determine if sertraline treatment vs. placebo will improve: a. nutritional status; b. adherence to prescribed medications; c. cognitive functioning; and d. markers of inflammation.
5 Recruiting Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
Conditions: Cryptococcal Meningitis;   Fungal Meningitis
Intervention: Drug: Sertraline
Outcome Measures: Survival;   Safety;   Intolerance;   Microbiologic;   Neurocognitive Performance;   Early Fungicidal Activity;   IRIS and Relapse Incidence
6 Unknown  The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
Conditions: Bipolar Affective Disorders;   Cyclothymic Disorder;   Schizoaffective Disorder;   Major Depressive Disorder;   Dysthymic Disorder;   Obsessive-Compulsive Disorder;   Panic Disorder;   Posttraumatic Stress Disorder;   Premenstrual Dysphoric Disorder;   Social Anxiety Disorder
Intervention:
Outcome Measures: blood levels of lithium or sertraline;   Fluctuations in symptom severity;   Correlations between Symptom Severity and Blood Levels of Drugs
7 Recruiting Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness
Conditions: Vestibular Migraine;   Chronic Subjective Dizziness
Interventions: Drug: Verapamil;   Drug: Sertraline
Outcome Measures: Change in severity of headache and dizziness in Daily Symptom Dairy;   Change in score of Migraine Disability Assessment (MIDAS);   Change in score of Dizziness Handicap Inventory (DHI);   Change in score of Migraine-Specific Quality of Life (MSQ)
8 Recruiting Trial of Sertraline to Treat Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: Sertraline;   Drug: Placebo
Outcome Measures: Mullen Scales of Early Learning;   Clinical Global Impression;   Autism Diagnostic Observation Schedule;   Visual Analog Scale;   Eye tracking;   Preschool Language Scale;   Sensory Processing Measure;   Sensory Profile
9 Recruiting Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
Conditions: Phobia, Social;   Panic Disorder;   Agoraphobia;   Obsessive-Compulsive Disorder;   Anxiety Disorders;   Major Depressive Disorder
Interventions: Drug: Sertraline;   Drug: Placebo
Outcome Measures: Clinical Global Impression - Improvement ≤ 2;   Liebowitz Social Anxiety Scale [LSAS] (mean change from baseline);   Mean change from baseline on the following scales: Quality of Life and Employment Satisfaction Questionnaire;   Sheehan Disability Scale;   Social Phobia Scale;   Brief Social Phobia Scale;   Penn State Worry Questionnaire;   Panic and Agoraphobia Scale;   Davidson Trauma Scale;   Social Anxiety Spectrum Self-Report (SHY-SR);   Yale-Brown Obsessive Compulsive Scale;   Montgomery-Asberg Depression Rating Scale (MADRS)
10 Recruiting Riluzole Augmentation Pilot in Depression (RAPID) Trial
Condition: Major Depressive Disorder
Interventions: Drug: Riluzole;   Drug: Sertraline;   Other: placebo
Outcome Measures: Mean change in Hamilton Depression Rating Scale (HDRS) score from baseline to endpoint at 8 weeks;   Proportion of patients experiencing an antidepressant response (>50% reduction in HDRS) at endpoint of 8 weeks;   Proportion of patients experiencing remission from depression (HDRS<7) at endpoint of 8 weeks;   Mean change in Hamilton Anxiety Rating Scale (HARS) score from baseline to endpoint at 8 weeks;   Mean change in Clinical Global Impression (CGI) scale from baseline to endpoint at 8 weeks
11 Unknown  The Effects of Sertraline on Depression in Parkinson's Disease
Conditions: Depression;   Parkinson's Disease
Intervention: Drug: Sertraline
Outcome Measures: change from baseline in Hamilton Depression Rating Scale;   change from baseline in questionnaire of PDQ-39
12 Not yet recruiting Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS
Condition: Pandas
Interventions: Drug: Sertraline+Antibiotic (penicillin/azithromycin);   Drug: Sertraline+placebo;   Biological: IVIG
Outcome Measures: The improvement of OC/tic symptoms will be superior in patients treated with SSRI+AB and in case with IVIG, compared with those treated with SSRI+placebo, as assessed by the YBOCS/YGTSS;   The degree of treatment response is expected to correlate with the percentage reduction in antibodies titers following IVIG administration;   The degree of treatment response is also expected to correlate with decreased inflammation in specific regions of the brain, as demonstrated by macroscopic changes and microstructural alterations on MRI and serum and CSF cytokines and chemokines
13 Recruiting Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
Condition: Obsessive Compulsive Disorder
Interventions: Drug: sertraline;   Behavioral: psychotherapy
Outcome Measures: change in cognitive function as measured by Trails B (Trail Making Test) and BRIEF (Behavior Rating Inventory of Executive Function) exams;   change in emotional regulation as measured by the emotional regulation factor from the BRIEF (Behavior Rating Inventory of Executive Function) exam;   change in suicide/aggression as measured by the HoNOSCA (Health of the Nation Outcome Scale for Children and Adolescents);   change in physical development as measured by height and weight;   change in pubertal development as measured by the PDS (Pubertal Development Scale);   change in clinical global impression scale -Improvement (CGI-I);   change in clinical global impression scale - Acceptability/Tolerability (CGI-A/T);   change in clinical global impression scale -Effectiveness (CGI-E);   change in clinical global impression scale -Severity (CGI-S);   change in clinical global assessment schedule -(CGAS);   Change in adverse event burden;   suicide-related events as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
14 Recruiting Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?
Conditions: Sexual Dysfunction;   Major Depressive Disorder
Interventions: Drug: Vilazodone;   Drug: Sertraline
Outcome Measure: Changes in Sexual Functioning Questionnaire (CSFQ (c))
15 Unknown  Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury
Condition: Traumatic Brain Injury
Interventions: Drug: Placebo;   Drug: Sertraline
Outcome Measures: Time to onset of DSM-IV defined mood and anxiety disorders; Total Community Integration Questionnaire scores at baseline, 3, and 6 months; Executive function composite will measure cognitive impairment.;   Overt Aggression Scale-Modified total score will quantify the degree of aggressive behavior.;   DSM-IV defined Personality change due to TBI (disinhibited, aggressive or combined types).;   Iowa Gambling Test score will measure the quality of decision making.;   Memory function composite will measure cognitive impairment.;   Neuroimaging variables;   SFE scores will measure the degree of satisfaction with social functioning at one year follow-up.;   Fractional anisotropy of frontal white matter will measure white matter integrity.
16 Recruiting The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
Conditions: Major Depressive Disorder;   Bipolar Disorder
Interventions: Other: chronobiological augmentation;   Drug: sertraline, lithium;   Radiation: one night of sleep deprivation and two FDG PET scans
Outcome Measure: Hamilton Rating Score for Depression
17 Recruiting The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders
Condition: Major Depressive Disorder
Interventions: Behavioral: problem solving therapy;   Drug: Sertraline
Outcome Measures: change in cerebral perfusion;   Change in cognitive measures of memory, learning, and executive dysfunction;   Change in BDNF
18 Unknown  Randomized Double Blinding Controlled Study on" Jia Wei Xiao Yao Jiaonang" Treating Mild to Moderate Major Depressive Disorder
Condition: Depressive Disorder
Interventions: Drug: Sertraline plus placebo of JWXYJN;   Drug: JWXYJN plus placebo of Sertraline
Outcome Measure: HAMD scale
19 Recruiting Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents
Conditions: Social Phobia;   Generalized Anxiety Disorder;   Separation Anxiety Disorder
Intervention: Drug: Sertraline
Outcome Measures: Clinical Global Impression (CGI) Scale;   Liebowitz Social Anxiety Scale (LSAS)
20 Unknown  Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury
Condition: Traumatic Brain Injury
Intervention: Drug: sertraline
Outcome Measures: Gouvier-PCSC;   Post Concussive Scale;   Hamilton Depression Scale;   Montgomery Asberg Depression Rating;   Diagnosis of PCD by DSM-IV;   Smell Identification Test

These studies may lead to new treatments and are adding insight into Zoloft etiology and treatment.

A major focus of Zoloft research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Zoloft